Meeting
2021 ASCO Annual Meeting
Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.
Authors
Dae Ho Lee
University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Dae Ho Lee , Aflah Roohullah , Byoung Chul Cho , Charlotte Rose Lemech , Paul L. de Souza , Michael Millward , Jun Young Choi , Kyung Eui Park , Minseon Lee , YeongMun Kim , YOUNGKEE Shin , Ji-Youn Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04052971
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3157)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3157
Abstract #
TPS3157
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar
Poster
2020 ASCO Virtual Scientific Program
First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.
First Author: Kyriakos P. Papadopoulos
Poster
2013 ASCO Annual Meeting
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
First Author: Michael Ong